Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2023-03-01
2024-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
NCT02594202
Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy
NCT05160597
Using PSMA PET-CT as a Diagnostic Tool for Detection of Prostatic Cancer at an Early Stage
NCT04116086
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features
NCT04825691
Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer
NCT03789253
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Following pathological analysis, paraffin slides will be undergo immunohistochemically staining for PKA, comparing cancerous tissue to normal surrounding tissue. the fresh frozen tissue will undergo western blot analysis for quantitative expression of PKA and its sub units.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
prostate biopsy
trans rectal ultrasound guided biopsies of prostate . Biopsy smaples will be referred to staining and western blot analysis.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical suspicion of prostate cancer
* Referred for biopsy
* Able to sign informed consent.
Exclusion Criteria
* Chronic prostatitis
* Previous prostate surgery
* Recent urinary tract infection (3 months prior to biopsy).
* Indwelling urinary catheter
50 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ziv Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ran Katz
Dr. Ran Katz, Head, department of Urology, ziv medical center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PKA-prostate
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.